Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET

Inclusion Criteria:

- Age greater than 3 years and less than 25 years

- Patients with classic histology or desmoplastic histology metastatic medulloblastoma
by histological diagnosis and by head and spine MRI.

- Patients with anaplastic histology will be excluded.

- Patients with high-risk supratentorial, non-metastatic, PNET

- Patients with metastatic PNET

- Newly diagnosed patients who have not received prior therapy, with the exception of
one short course of emergent chemotherapy in newly presenting patients with
neurological compromise per provider decision

- Only patients who are expected to survive at least 6 weeks will be eligible for this
study.

Exclusion Criteria:

- Patients who are pregnant may not be treated on this study